(1-甲基-1H-咪唑-2-基)甲胺双盐酸盐 | 53332-67-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1-甲基-1H-咪唑-2-基)甲胺双盐酸盐
• 英文名称: (1-Methyl-1H-imidazol-2-yl)methanamine dihydrochloride
• 英文别名: (1-methylimidazol-2-yl)methanamine;dihydrochloride
• CAS: 53332-67-5
• 化学式: C5H11Cl2N3
• 分子量: 184.06
• InChiKey: VOJQTCGJLJPNJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.72
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  43.8
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  (R/S)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid 、 N-甲基吗啉 、 (1-甲基-1H-咪唑-2-基)甲胺双盐酸盐 、 卡特缩合剂 在 desired product 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 以to give (R/S)-2-hydroxy-N-((1-methyl-1H-imidazol-2-yl)methyl)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide (4.9 mg, 0.001 mmol, 13% yield)的产率得到(R/S)-2-hydroxy-N-((1-methyl-1H-imidazol-2-yl)methyl)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide
  参考文献：
  名称：

  Mandelamide heterocyclic compounds

  摘要：

  本发明涉及式（I）的化合物或其立体异构体、盐或前药，其中：Q为，或R1为带有0至3个取代基的苯基；R1、R2、R3、R4、R5和G在此定义。本发明还涉及使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的制药组合物。这些化合物可用于治疗、预防或减缓多种治疗领域的疾病或障碍，例如自身免疫性疾病和血管疾病。

  公开号：

  US08835470B2

文献信息

• [EN] 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS<br/>[FR] AMIDES D'ACIDE 4-(5-ISOXAZOLYL OU 5-PYRAZOLYL-1,2,4-OXADIAZOL-3-YL)-MANDÉLIQUE COMME AGONISTES DU RÉCEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE DE TYPE 1
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011133734A1

  公开（公告）日：2011-10-27

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物或其立体异构体、盐或前药，其中：Q是，或者R1是苯基，其上取代基为零至3个；而R1、R2、R3、R4、R5和G在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。
• [EN] 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES<br/>[FR] COMPOSES DE 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDES EN TANT QU'INHIBITEURS DE PROTEINES KINASES UTILES POUR LE TRAITEMENT DE MALADIES OPHTALMIQUES
  申请人：PFIZER

  公开号：WO2004056806A1

  公开（公告）日：2004-07-08

  Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma,rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了可以调节和/或抑制眼科疾病和某些蛋白激酶活性的吲哚唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，从而调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效剂量来治疗眼科疾病和癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣。
• Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20040192735A1

  公开（公告）日：2004-09-30

  Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了调节和/或抑制眼科疾病和某些蛋白激酶活性的吲唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，从而调节和/或抑制不必要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗眼科疾病和与不必要的血管生成和/或细胞增殖相关的癌症和其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和银屑病。
• N-alkyl pyrroles as HMG-CoA reductase inhibitors
  申请人：Bratton D. Larry

  公开号：US20050154042A1

  公开（公告）日：2005-07-14

  HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided.

  提供了作为降低胆固醇和降脂化合物有用的HMGCo-A还原酶抑制剂化合物。还提供了该化合物的药物组成物。还提供了制备该化合物的方法和使用该化合物的方法。
• MANDELAMIDE HETEROCYCLIC COMPOUNDS
  申请人：Cherney Robert J.

  公开号：US20130045964A1

  公开（公告）日：2013-02-21

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R 1 is phenyl substituted with zero to 3 substituents; and R 1 , R 2 , R 3 , R 4 , R 5 , and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）的化合物或其立体异构体、盐或前药，其中：Q是，或R1是带有零到3个取代基的苯基；R1、R2、R3、R4、R5和G在此处被定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展中有用，例如自身免疫性疾病和血管疾病。